NCT00528645View on ClinicalTrials.gov

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

May 31, 2013

Conditions
Extensive Stage Small Cell Lung CancerLung MetastasesMalignant Pleural EffusionRecurrent Small Cell Lung Cancer
Interventions
DRUG

saracatinib

Given orally

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00528645 - AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter